p53 Variants in Cancer Risk and Therapy

p53 癌症风险和治疗的变异

基本信息

  • 批准号:
    9188088
  • 负责人:
  • 金额:
    $ 42.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-12-01 至 2020-11-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The p53 tumor suppressor gene is one of the most important genes in human cancer. Unlike the overwhelming majority of oncogenes and tumor suppressor genes, the TP53 gene is distinguished by the existence of single nucleotide polymorphisms in the coding region that alter p53 function. Several years ago we reported that a polymorphism at amino acid 47 (Pro47Ser, rs1800371) of TP53 occurs in 1:40 African Americans and up to 1:10 of Africans; this polymorphism markedly impairs the phosphorylation of p53 on a critical residue, serine 46, and also significantly impairs the apoptotic ability of p5. In order to assess the impact of this polymorphism on cancer risk and therapy, we created a mouse model for the S47 variant, compared to wild type p53. We also analyzed human lymphoblastoid cell lines that are homozygous for the S47 variant, compared to WT p53. We show in both our mice and in human cells that the S47 variant has markedly decreased ability to induce apoptosis in response to stress, along with decreased ability to transactivate a subset of p53 target genes (Noxa, GLS2 and Sco2), accompanied by a failure to be phosphorylated on serine 46. We show that cells with S47 have dramatic resistance to many chemotherapeutic agents, yet increased sensitivity to others. Surprisingly, we find that S47 mice are cancer- prone, and further that S47 male mice develop spontaneous prostate hyperplasia. In preliminary human studies we show data indicating that the S47 allele may be a significant risk factor for prostate cancer in African American men. The broad, long term objective of this proposal is to test the hypothesis that the impaired function of S47 leads to reduced ability to suppress prostate cancer initiation and progression. We also seek to test the hypothesis that chemotherapy in S47 individuals can be personalized. There are two aims. In Aim 1, our mouse models for WT and S47 will be used to test the function of S47 in the initiation, progression, and chemotherapy of prostate cancer. In Aim 2, we will analyze human prostate cancer samples from African American men, and test the hypothesis that the S47 variant is associated with increased prostate cancer risk and/or aggressiveness. Importantly, information from each aim will be used to inform the other. For these goals, we have combined the expertise of four laboratories, three of which are located on the same campus (Murphy, Altieri and Rebbeck), and two of which have long-standing expertise in the epidemiology of human prostate cancer (Rebbeck and Isaacs). Each group has unique and complementary expertise in mouse models of cancer, p53 function, and epidemiology of prostate cancer in men of African descent. The proposed research marks the first time that the impact of this deleterious polymorphism on cancer risk and therapy in individuals of African descent will be assessed.
 描述(申请人提供):p53抑癌基因是人类癌症中最重要的基因之一。与绝大多数癌基因和抑癌基因不同,TP53 基因的特点是编码区存在改变 p53 功能的单核苷酸多态性。几年前,我们报道了 TP53 氨基酸 47(Pro47Ser,rs1800371)的多态性发生在 1:40 的非洲裔美国人和高达 1:10 的非洲人中;这种多态性显着损害了 p53 在关键残基丝氨酸 46 上的磷酸化,并且还显着损害了 p5 的凋亡能力。为了评估这种多态性对癌症风险和治疗的影响,我们创建了 S47 变体的小鼠模型,与野生型 p53 进行比较。我们还分析了与 WT p53 相比 S47 变体纯合的人淋巴母细胞系。我们在小鼠和人类细胞中都发现,S47 变体在应激反应中诱导细胞凋亡的能力显着降低,同时反式激活 p53 靶基因子集(Noxa、GLS2 和 Sco2)的能力也降低,同时丝氨酸 46 无法磷酸化。我们发现,带有 S47 的细胞对许多化疗药物具有显着的耐药性,但敏感性增加 给其他人。令人惊讶的是,我们发现S47小鼠容易患癌症,而且S47雄性小鼠会出现自发性前列腺增生。在初步人体研究中,我们显示的数据表明 S47 等位基因可能是非裔美国男性患前列腺癌的一个重要危险因素。该提案的广泛、长期目标是检验以下假设:S47 功能受损会导致抑制前列腺癌发生和进展的能力降低。我们还试图检验 S47 个体的化疗可以个性化的假设。有两个目标。在目标 1 中,我们的 WT 和 S47 小鼠模型将用于测试 S47 在前列腺癌的发生、进展和化疗中的功能。在目标 2 中,我们将分析来自非裔美国男性的人类前列腺癌样本,并检验 S47 变异与前列腺癌风险和/或侵袭性增加相关的假设。重要的是,每个目标的信息将用于告知另一个目标。为了实现这些目标,我们结合了四个实验室的专业知识,其中三个实验室位于同一校园(Murphy、Altieri 和 Rebbeck),其中两个实验室(Rebbeck 和 Isaacs)在人类前列腺癌流行病学方面拥有长期的专业知识。每个小组在小鼠癌症模型、p53 功能和非洲裔男性前列腺癌流行病学方面都有独特且互补的专业知识。这项拟议的研究标志着首次评估这种有害多态性对非洲人后裔癌症风险和治疗的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maureen E. Murphy其他文献

RETRACTED ARTICLE: IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance
撤回文章:IspH 抑制剂杀死革兰氏阴性菌并动员免疫清除
  • DOI:
    10.1038/s41586-020-03074-x
  • 发表时间:
    2020-12-23
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Kumar Sachin Singh;Rishabh Sharma;Poli Adi Narayana Reddy;Prashanthi Vonteddu;Madeline Good;Anjana Sundarrajan;Hyeree Choi;Kar Muthumani;Andrew Kossenkov;Aaron R. Goldman;Hsin-Yao Tang;Maxim Totrov;Joel Cassel;Maureen E. Murphy;Rajasekharan Somasundaram;Meenhard Herlyn;Joseph M. Salvino;Farokh Dotiwala
  • 通讯作者:
    Farokh Dotiwala
Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex
线粒体 p53 激活 Bak 并导致 Bak-Mcl1 复合物的破坏
  • DOI:
    10.1038/ncb1123
  • 发表时间:
    2004-04-11
  • 期刊:
  • 影响因子:
    19.100
  • 作者:
    J. I-Ju Leu;Patrick Dumont;Michael Hafey;Maureen E. Murphy;Donna L. George
  • 通讯作者:
    Donna L. George
Kaposi’s sarcoma-associated herpesvirus induces mitochondrial fission to evade host immune responses and promote viral production
卡波西肉瘤相关疱疹病毒诱导线粒体分裂以逃避宿主免疫反应并促进病毒产生
  • DOI:
    10.1038/s41564-025-02018-3
  • 发表时间:
    2025-05-22
  • 期刊:
  • 影响因子:
    19.400
  • 作者:
    Qing Zhu;Robert McElroy;Janvhi Suresh Machhar;Joel Cassel;Zihan Zheng;Behzad Mansoori;Hongrui Guo;Sen Guo;Christian Pangilinan;Jinghui Liang;Dongliang Shen;Lu Zhang;Qin Liu;Andrew V. Kossenkov;Dario C. Altieri;Paul M. Lieberman;Shou-Jiang Gao;Pinghui Feng;Maureen E. Murphy;Jikui Song;Joseph M. Salvino;Qiming Liang;Jae U. Jung;Chengyu Liang
  • 通讯作者:
    Chengyu Liang

Maureen E. Murphy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maureen E. Murphy', 18)}}的其他基金

Functional Analysis of p53 Polymorphic Variants - Diversity Supplement
p53 多态性变体的功能分析 - Diversity Supplement
  • 批准号:
    10818904
  • 财政年份:
    2023
  • 资助金额:
    $ 42.14万
  • 项目类别:
The genetics of tumor suppression by p53
p53 抑制肿瘤的遗传学
  • 批准号:
    10636305
  • 财政年份:
    2023
  • 资助金额:
    $ 42.14万
  • 项目类别:
Purchase of a SARRP 200 Platform for Irradiation
购买 SARRP 200 辐照平台
  • 批准号:
    10430904
  • 财政年份:
    2022
  • 资助金额:
    $ 42.14万
  • 项目类别:
The impact of coding region variants on mutant p53 biology
编码区变异对突变 p53 生物学的影响
  • 批准号:
    10304135
  • 财政年份:
    2019
  • 资助金额:
    $ 42.14万
  • 项目类别:
The impact of coding region variants on mutant p53 biology
编码区变异对突变 p53 生物学的影响
  • 批准号:
    10523512
  • 财政年份:
    2019
  • 资助金额:
    $ 42.14万
  • 项目类别:
The impact of coding region variants on mutant p53 biology
编码区变异对突变 p53 生物学的影响
  • 批准号:
    9914543
  • 财政年份:
    2019
  • 资助金额:
    $ 42.14万
  • 项目类别:
The impact of coding region variants on mutant p53 biology
编码区变异对突变 p53 生物学的影响
  • 批准号:
    10063505
  • 财政年份:
    2019
  • 资助金额:
    $ 42.14万
  • 项目类别:
p53 Variants in Cancer Risk and Therapy
p53 癌症风险和治疗的变异
  • 批准号:
    9007017
  • 财政年份:
    2015
  • 资助金额:
    $ 42.14万
  • 项目类别:
p53 Variants in Cancer Risk and Therapy
p53 癌症风险和治疗的变异
  • 批准号:
    9377535
  • 财政年份:
    2015
  • 资助金额:
    $ 42.14万
  • 项目类别:
Tuberculosis Surveillance, Prevention and Control, and Laboratory Upgrade
结核病监测、预防和控制以及实验室升级
  • 批准号:
    8009855
  • 财政年份:
    2010
  • 资助金额:
    $ 42.14万
  • 项目类别:

相似海外基金

African Rare Diseases Initiative (ARDI): Advancing Genomic Medicine through rare diseases research in Africa
非洲罕见疾病倡议 (ARDI):通过非洲罕见疾病研究推进基因组医学
  • 批准号:
    10674660
  • 财政年份:
    2023
  • 资助金额:
    $ 42.14万
  • 项目类别:
French foreign policy in West-Africa revisited: examining French monetary and military influence on African sovereignty
重新审视法国在西非的外交政策:审视法国货币和军事对非洲主权的影响
  • 批准号:
    2887041
  • 财政年份:
    2023
  • 资助金额:
    $ 42.14万
  • 项目类别:
    Studentship
Seamen from the African Indian Ocean, 1880s-1940s: Transnational Labour Relations between Africa and Europe in Colonial Times
来自非洲印度洋的海员,1880 年代至 1940 年代:殖民时期非洲和欧洲之间的跨国劳资关系
  • 批准号:
    23K00793
  • 财政年份:
    2023
  • 资助金额:
    $ 42.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Role of Kaiso as a predictive breast cancer biomarker in Africa and across the African Diaspora
Kaiso 作为非洲和整个非洲侨民的乳腺癌预测生物标志物的作用
  • 批准号:
    10347874
  • 财政年份:
    2022
  • 资助金额:
    $ 42.14万
  • 项目类别:
Pan-African Frontiers And Identities: The Remaking Of Africa In World Politics
泛非边界和身份:世界政治中非洲的重塑
  • 批准号:
    MR/W012103/1
  • 财政年份:
    2022
  • 资助金额:
    $ 42.14万
  • 项目类别:
    Fellowship
Southern African Research Consortium for Mental health INTegration (S-MhINT)-Research and capacity building consortium to strengthen mental health integration in South Africa, Mozambique and Tanzania.
南部非洲心理健康一体化研究联盟 (S-MhINT) - 研究和能力建设联盟,旨在加强南非、莫桑比克和坦桑尼亚的心理健康一体化。
  • 批准号:
    10613603
  • 财政年份:
    2022
  • 资助金额:
    $ 42.14万
  • 项目类别:
The timing and geography of African ape and human origins: New evidence from Europe, Africa and Asia.
非洲猿和人类起源的时间和地理:来自欧洲、非洲和亚洲的新证据。
  • 批准号:
    RGPIN-2016-06761
  • 财政年份:
    2021
  • 资助金额:
    $ 42.14万
  • 项目类别:
    Discovery Grants Program - Individual
The definition of "Africa" and the concept of "race" in Pan-African movements
“非洲”的定义与泛非运动中的“种族”概念
  • 批准号:
    20K22009
  • 财政年份:
    2020
  • 资助金额:
    $ 42.14万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Re-examining the anti-colonial discourses in former Portuguese Africa: How African press argued
重新审视前葡属非洲的反殖民话语:非洲媒体如何争论
  • 批准号:
    20K12353
  • 财政年份:
    2020
  • 资助金额:
    $ 42.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The timing and geography of African ape and human origins: New evidence from Europe, Africa and Asia.
非洲猿和人类起源的时间和地理:来自欧洲、非洲和亚洲的新证据。
  • 批准号:
    RGPIN-2016-06761
  • 财政年份:
    2020
  • 资助金额:
    $ 42.14万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了